-
My Account
My Account
BSE Live
Jan 18, 16:00Prev. Close
5207.60
Open Price
5212.00
Bid Price (Qty.)
5042.05 (1)
Offer Price (Qty.)
5052.80 (8)
NSE Live
Jan 18, 16:03Prev. Close
5212.80
Open Price
5231.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
5052.10 (30)
| Yearly Results of Dr Reddys Laboratories (in Rs. Cr.) | Mar '20 | Mar '19 | Mar '18 | Mar '17 | Mar '16 | |
| Net Sales/Income from operations | 11,803.00 | 10,466.70 | 9,302.60 | 9,628.10 | 10,234.80 | |
| Other Operating Income | 47.40 | 158.80 | 56.70 | 91.70 | 57.10 | |
| Total Income From Operations | 11,850.40 | 10,625.50 | 9,359.30 | 9,719.80 | 10,291.90 | |
| EXPENDITURE | ||||||
| Consumption of Raw Materials | 2,556.50 | 2,103.20 | 2,011.00 | 1,817.60 | 2,072.70 | |
| Purchase of Traded Goods | 1,117.20 | 868.60 | 671.60 | 671.50 | 610.40 | |
| Increase/Decrease in Stocks | -99.90 | 66.00 | -51.60 | 1.90 | -28.80 | |
| Power & Fuel | -- | -- | -- | -- | -- | |
| Employees Cost | 2,030.20 | 1,931.90 | 1,843.00 | 1,803.30 | 1,693.40 | |
| Depreciation | 789.20 | 780.60 | 774.10 | 735.10 | 927.50 | |
| Excise Duty | -- | -- | -- | -- | -- | |
| Admin. And Selling Expenses | -- | -- | -- | 998.50 | 649.50 | |
| R & D Expenses | -- | -- | -- | -- | -- | |
| Provisions And Contingencies | -- | -- | -- | -- | -- | |
| Exp. Capitalised | -- | -- | -- | -- | -- | |
| Other Expenses | 3,376.80 | 3,356.10 | 3,555.40 | 2,681.40 | 2,951.40 | |
| P/L Before Other Inc. , Int., Excpt. Items & Tax | 2,080.40 | 1,519.10 | 555.80 | 1,010.50 | 1,415.80 | |
| Other Income | 743.20 | 238.40 | 204.00 | 591.20 | 324.90 | |
| P/L Before Int., Excpt. Items & Tax | 2,823.60 | 1,757.50 | 759.80 | 1,601.70 | 1,740.70 | |
| Interest | 47.80 | 56.80 | 62.80 | 57.20 | 64.10 | |
| P/L Before Exceptional Items & Tax | 2,775.80 | 1,700.70 | 697.00 | 1,544.50 | 1,676.60 | |
| Exceptional Items | -- | -- | -- | -- | -- | |
| P/L Before Tax | 2,775.80 | 1,700.70 | 697.00 | 1,544.50 | 1,676.60 | |
| Tax | -161.90 | 423.40 | 130.10 | 160.40 | 302.30 | |
| P/L After Tax from Ordinary Activities | 2,937.70 | 1,277.30 | 566.90 | 1,384.10 | 1,374.30 | |
| Prior Year Adjustments | -- | -- | -- | -- | -- | |
| Extra Ordinary Items | -- | -- | -- | -- | -- | |
| Net Profit/(Loss) For the Period | 2,937.70 | 1,277.30 | 566.90 | 1,384.10 | 1,374.30 | |
| Equity Share Capital | 83.10 | 83.00 | 83.00 | 82.90 | 85.30 | |
| Reserves Excluding Revaluation Reserves | 15,108.80 | 12,601.10 | 11,724.80 | 11,517.70 | 11,520.10 | |
| Equity Dividend Rate (%) | 500.00 | 400.00 | 400.00 | 400.00 | 400.00 | |
| EPS Before Extra Ordinary | ||||||
| Basic EPS | 177.23 | 76.98 | 34.19 | 83.05 | 80.59 | |
| Diluted EPS | 176.88 | 76.85 | 34.12 | 82.88 | 80.34 | |
| EPS After Extra Ordinary | ||||||
| Basic EPS. | 177.23 | 76.98 | 34.19 | 83.05 | 80.59 | |
| Diluted EPS. | 176.88 | 76.85 | 34.12 | 82.88 | 80.34 | |
| Public Share Holding | ||||||
| No Of Shares (Crores) | -- | -- | -- | -- | -- | |
| Share Holding (%) | -- | -- | -- | -- | -- | |
| Promoters and Promoter Group Shareholding | ||||||
| a) Pledged/Encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- | |
| b) Non-encumbered | ||||||
| - Number of shares (Crores). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company). | -- | -- | -- | -- | -- |
29.10.2020
Dr Reddys Labs Consolidated September 2020 Net Sales at Rs 4,910.90 crore, up 2.04% Y-o-Y
29.10.2020
Dr Reddys Labs Standalone September 2020 Net Sales at Rs 3,345.80 crore, down 2.91% Y-o-Y
28.10.2020
Dr Reddy's Labs Q2 profit falls 30% to Rs 762 crore, global generics business up 21%
29.08.2020
18.01.2021
Dr. Reddy’s Laboratories Q3 PAT may dip 2% YoY to Rs. 781.6 cr: Prabhudas Lilladher
29.07.2020
Dr Reddy's Labs Q1 Preview: Profit may decline on higher base, but revenue can grow over 5%
14.10.2019
12.07.2019
Dr. Reddy’s Laboratories Q1 PAT seen up 13.6% YoY to Rs. 540.8 cr: Prabhudas Lilladher
